Eli Lilly said Tuesday that it will start providing low-dose vials of its obesity drug Zepbound through its direct-to-consumer platform, a move that will likely ease supply constraints and draw ...

Drugmaker Eli Lilly said Tuesday it will sell single-use vials of its weight-loss drug Zepbound at a fraction of the price of its pens, amid skyrocketing demand among Americans for anti-obesity ...

Eli Lilly & Co. LLY said Tuesday that patients can now access 2.5- and 5-milligram single-dose vials of its weight-loss treatment Zepbound with an on-label prescription at a discount of at least ...

Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Credit: Ciara Kimsey/Shutterstock. Eli Lilly and Company has announced the availability of Zepbound (tirzepatide) in 2.5mg and 5mg single-dose vials for self-pay for adults with obesity. The move ...

This form of Zepbound is sold as a vial that needs to be given by a syringe, although patients can still do it themselves. Zepbound and Mounjaro are both brand names for tirzepatide. However ...

Through its online pharmacy LillyDirect, Eli Lilly announced Tuesday it will allow patients to purchase single-dose vials of Zepbound—without the autoinjector—at a 50% discount or more versus other ...